Hokusai-VTE Cancer, 2017 trial summary

A randomised clinical trial investigating the effect of edoxaban versus dalteparin in patients with cancer who had acute symptomatic or incidental venous thromboembolism

Studied treatment	low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily. Treatment was given for atleast 6 months and up to 12 months.
Control treatment	subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily

Patients	patients with cancer who had acute symptomatic or incidental venous thromboembolism
Group sizes	522 / 524

Blindness	open label	Inclusion period
Follow-up duration		Centers
Lost to FU		geographical localisation
Primary endpoint	recurrent venous thromboembolism or major bleeding at12 months	Design

Raskob GE Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018;378:615-624 [PMID: 29231094] link to pdf add to Mendeley

ClinicalTrial.gov record NCT02073682

Registering number	NCT02073682 (see trial on clinicaltrials.gov)
Code Name